Aminu Bello, MD, PhD, FRCPC, FACP, FASN
Dr Bello is a professor of medicine at the University of Alberta, and Consultant Nephrologist at the University of Alberta Hospital. He qualified as a medical doctor in Nigeria at Usmanu Danfodiyo University, Sokoto, and underwent specialist clinical training in internal medicine, nephrology, and epidemiology in Nigeria, UK and Canada. He holds research grants from major provincial and national research organizations including CIHR. He has published original research work in major general medical journals including the Lancet, JAMA and the BMJ. He reviews regularly for the major general medical and nephrology journals including The Lancet, JAMA, BMJ and Kidney International. He has more than 200 peer-reviewed scientific publications (articles, book chapters and monographs), and is keenly interested in global health initiatives to improve nephrology practice and education in emerging nations. He is currently a Co-Chair for the International Society of Nephrology (ISN) Global Kidney Health Atlas (GKHA) Project; an initiative for the development and implementation of strategies to enhance global equity in kidney care across all regions and countries of the world.
Clara Bohm, MD, FRCPC, MPH
Dr. Bohm is an associate professor of internal medicine at the University of Manitoba and a nephrologist in the Manitoba Renal Program. She is cross-appointed to the Department of Community Health Sciences and a research affiliate with the Health, Leisure and Human Performance Institute, Faculty of Kinesiology and Recreation Management, University of Manitoba. Her clinical and research interests focus on improving quality of life in people on dialysis. She leads the Can-SOLVE CKD Triple I Project, striving to identify challenges and develop solutions to improve patient-centred care in hemodialysis. She also leads several nationally funded clinical trials that aim to characterize the effect of exercise on symptom burden and functional status in individuals on hemodialysis. As an "early adopter" of patient engagement, Dr. Bohm works to highlight and incorporate the perspectives of individuals with kidney disease in all her clinical and research endeavours.
Darren Bridgewater, PhD
Dr. Bridgewater is an associate professor in the Department of Pathology and Molecular Medicine at McMaster University. Dr. Bridgewater obtained his PhD in the Department of Anatomy and Cell Biology at the University of Western Ontario, and completed his post-doctoral fellowship in Developmental Biology at the Hospital For Sick Children, University of Toronto. Congenital anomalies of the kidney and urinary tract (CAKUT) comprise a pleitrophic group of developmental anomalies arising from a fundamental failure in normal kidney development, and constitute the major cause of childhood renal failure. Dr. Bridgewater research focusses on elucidating the fundamental molecular mechanisms underlying normal kidney development to advance our understanding of mechanisms that lead to disease. Dr. Bridgewater’s research is funded by Kidney Foundation of Canada, NSERC and CIHR.
Dylan Burger, PhD, ISHF
Dr. Burger is a senior scientist at the Ottawa Hospital Research Institute and Associate Professor at the University of Ottawa (Department of Cellular and Molecular Medicine). He holds a PhD in Physiology and Pharmacology from the University of Western Ontario and completed post-doctoral studies with Drs. Rhian Touyz and Kevin Burns at the Ottawa Hospital Research Institute. His independent research program focuses on understanding the molecular underpinnings of diabetes and hypertension and their associated renal complications. In particularly he has been active in the study of extracellular vesicles as markers and mediators of vascular and renal injury for more than 10 years. He has authored more than 100 manuscripts and has received several awards including the 2016 Canadian Society of Nephrology New Investigator Lectureship and the 2018 University of Ottawa Department of Medicine PhD Scientist Award. Dr. Burger was also the recipient of a 2014 New Investigator Award from the KRESCENT program (kidney research scientist core education and national training program) which is a joint initiative through the Kidney Foundation of Canada, Canadian Society of Nephrology and the Canadian Institute of Health Research.
He is the current chair of Communications for the International Society of Hypertension. Dr. Burger is a founding member of The Lancet Commission on Hypertension and associate editor for the European Heart Journal and the Journal of Extracellular Vesicles. He was co-chair of the first Molecules and Mechanisms Mediating Kidney Health and Disease Symposium in 2021.
Mark Canney, MD, PhD, FRCPC
Dr. Mark Canney is an assistant professor in the Department of Medicine at the University of Ottawa, associate scientist at the Ottawa Hospital Research Institute, and staff nephrologist at the Ottawa Hospital. He completed his undergraduate medical degree at National University of Ireland Galway and undertook his internal medicine and nephrology training in Ireland. He completed a PhD in population health epidemiology at Trinity College Dublin in 2017 before moving to Canada to pursue a post-doctoral research fellowship at the University of British Columbia under the mentorship of Dr. Adeera Levin and Dr. Sean Barbour. It was there that he cultivated his research interests in the epidemiology of glomerular disease and refining our understanding of clinical outcomes in patients with different types of kidney disease. With the support of the KRESCENT program, Dr. Canney seeks to improve the awareness, assessment and management of cardiovascular risk among patients with glomerular disease.
Maoliosa Donald, PhD
Dr. Donald is an adjunct assistant professor in the Cumming School of Medicine (Division of Nephrology) at the University of Calgary and is an implementation consultant with The Center for Implementation. She is a health services researcher and physical therapist. Dr. Donald’s research interests include interventions that support person-centered care, and innovations that address the evidence-practice gap for patients with early chronic kidney disease.
Meghan Elliott, MD, MSc, FRCPC
Dr. Elliott is a clinician scientist with clinical training in nephrology and a research focus in chronic kidney disease care delivery. Dr. Elliott's program of research employs primarily qualitative and mixed methods to understand patients' needs and priorities, identify care gaps, and develop interventions that support self-management and integrated care in the community. Examples of projects related to this theme include the implementation of patient-reported outcome measures in hemodialysis care, shared decision-making in dialysis-related treatment decisions, and patient-centered models of urgent care delivery. Dr. Elliott engages with patients as partners throughout her research.
Gregory Hundemer, MD, MPH, FRCPC
Dr. Hundemer is a staff nephrologist at the Ottawa Hospital, an assistant professor of medicine with a cross-appointment in the School of Epidemiology and Public Health at the University of Ottawa, and an associate scientist at the Ottawa Hospital Research Institute. Dr. Hundemer completed his internal medicine and nephrology training at Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School. His research interests involve understanding the clinical implications of overt and subclinical forms of aldosterone excess and improving treatment approaches for these conditions. His research has been funded by the CIHR, NIH, Kidney Foundation of Canada, KRESCENT New Investigator Award, and Lorna Jocelyn Wood Chair in Kidney Research.
Ngan Lam, MD, MSc, FRCPC
Dr. Lam is a clinician scientist, transplant nephrologist and associate professor, Division of Nephrology at the University of Calgary. She completed her fellowships in nephrology and clinical kidney transplantation at Western University. Dr. Lam also completed her Master of Science in clinical epidemiology and biostatistics at Western University and is a graduate of the KRESCENT post-doctoral fellowship (2012-2015). She was awarded the KRESCENT new investigator award (2015-2018) to continue her research on the long-term outcomes of kidney transplant recipients and living kidney donors.
François Madore, MD, MSc, FRCPC
Dr. Madore is a professor in the Department of Medicine, Chair of the Department of Medicine at the University of Montreal, and a nephrologist at the Hôpital du Sacré-Coeur de Montréal. Following completion of medical school at the University of Montreal, Dr. Madore completed his MSc in epidemiology at the Harvard School of Public Health.
Dr. Madore's main research interests are biomarkers and cardiovascular complications in patients with end-stage renal disease. His research has been funded by the Fonds de la recherche en santé du Québec, the Canadian Institutes of Health Research and the Kidney Foundation of Canada. Dr Madore is the author of more than 100 articles and abstracts in scientific journals in the fields of nephrology and cardiology.
Thomas Mavrakanas, MD, MSc, FRCPC
Dr. Mavrakanas is a clinician scientist, nephrologist, and assistant professor at McGill University. His research has been focused on the causes of and treatments for cardiovascular disease in patients with chronic kidney disease and end-stage renal disease. Dr. Mavrakanas has 60 peer-reviewed publications and has received multiple competitive peer-reviewed grants or scholarships. Dr. Mavrakanas received his medical diploma and a Master of Science degree in medical research methodology from the Aristotle University in Thessaloniki, Greece, in 2001 and 2006, respectively. Having completed his specialty training in internal medicine in France and Switzerland between 2006 and 2011, he obtained an attending physician job at Geneva University Hospitals in Switzerland in 2012. After two years of subspecialty training in nephrology at McGill University, Dr. Mavrakanas did a research fellowship at Brigham & Women’s Hospital, Harvard Medical School. He then returned to Geneva University in 2017 and was promoted to the rank of Privat-Dozent (habilitation thesis) prior to joining McGill University Health Center in 2020.
Amber Molnar, MD, MSc, FRCPC
Dr. Molnar is an associate professor with the Department of Medicine, Division of Nephrology at McMaster University and holds a cross appointment with the Department of Health Research Methods, Evidence and Impact. She received her MD at the University of Saskatchewan and completed Internal Medicine training at Western University. She then completed her Nephrology training followed by a two-year research fellowship and MSc in Epidemiology at the University of Ottawa. She is an adjunct scientist with ICES. In this role, she is able to use large, provincial healthcare databases to answer research questions pertinent to patients with kidney disease. Her research program focuses primarily on improving outcomes for patients with chronic kidney disease and on hemodialysis. She also serves as an associate editor for the Canadian Journal of Kidney Health and Disease, the official journal of the Canadian Society of Nephrology, and is the co-Lead on the Communications and Engagement for the Canadian Nephrology Trials Network.
Keigan More, MD, MSc, FRPC
Associate Editor of Case Reports
Dr. More is a nephrologist and assistant professor in the Department of Medicine at Dalhousie University. He received his MD at the University of British Columbia and completed Internal Medicine and Nephrology training at Dalhousie University. He completed a Master of Science in Quality Improvement and Patient Safety at the Institute of Health Policy, Management and Evaluation at the University of Toronto. He currently serves as the medical director of Renal Quality for the Nova Scotia Renal Program Central Zone and is program director of the Dalhousie University Adult Nephrology training program.
Ramesh Prasad, MD, MSc, PhD, FRCPC
Dr. Prasad is a nephrologist, professor of medicine at the University of Toronto, and director of the Kidney Transplant Program at St. Michael’s Hospital. Dr. Prasad obtained his medical degree from Osmania University, Hyderabad, India. He completed his internal medicine residency at Wayne State University / Detroit Medical Center, his nephrology fellowship at the University of Pittsburgh Medical Center, and a transplantation nephrology fellowship at Toronto General Hospital. Dr. Prasad holds a Master of Science degree in medical science from the University of Toronto and a PhD in philosophy. Dr. Prasad’s research interest includes all aspects pertinent to the long-term health of both kidney transplant recipients and donors, and the philosophy of science and medicine. He has published over 130 peer-reviewed articles. He is certified and recertified in both internal medicine and nephrology by the American Board of Internal Medicine and has a specialist certificate in hypertension from the American Society of Hypertension. He serves on the Declaration of Istanbul Custodian Group, Canadian Hypertension Education Program, and various committees of the Canadian and American Societies of Transplantation.
Claudio Rigatto, MD, MSc, FRCPC
Dr. Rigatto is an associate professor at the University of Manitoba Faculty of Medicine and an attending nephrologist at both St. Boniface and Seven Oaks General Hospitals. He received his medical training at the University of Manitoba, including a BSc. in Medicine and at Memorial University in Newfoundland where he received his MSc. in Medicine. Dr. Rigatto is a clinical epidemiologist and serves as chair of the Can-SOLVE CKD Network Research Operations Committee.
Dr. Rigatto’s research is focused on biomarkers as predictors of outcomes in both acute and chronic kidney disease. He is a lead investigator with the Winnipeg Cardiac Surgery Cohort, a prospective cohort study of renal outcomes after heart surgery, where his research focuses on intraoperative biomarkers of acute kidney injury. He is also one of the lead investigators for the CanPREDDICT Consortium, a prospective cohort of 2500 CKD patients followed by nephrologists across Canada exploring utility of newer markers of renal and vascular health in prediction of patient-important outcomes in CKD.